ESTRO 2025 - Abstract Book

S1260

Clinical – Lower GI

ESTRO 2025

Conclusion: This study highlights the safety and efficacy of MRIgSBRT in PC patients, including its integration with PARP inhibitors, enabling PTV dose escalation while sparing OARs. The treatment was well tolerated, with no reported toxicities.

Keywords: MRgRT, peritoneal carcinosis, SBRT

References 1. Case Report: First in Human Online Adaptive MR Guided SBRT of Peritoneal Carcinomatosis Nodules: A New Therapeutic Approach for the Oligo-Metastatic Patient. Boldrini et al. Front Oncol., 2020 2.The role of PARP inhibitors in the treatment of gynecologic malignancies. Reinbolt et al. Front. Oncol., 2013 3.Diagnosis and treatment of peritoneal carcinomatosis – a comprehensive overview. Szadkowska et al. Pol J Radiol., 2023